• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙酮酸激酶缺乏症:网织红细胞丙酮酸激酶活性显著降低以及丙酮酸激酶/己糖激酶比值的特异性有限。

Pyruvate Kinase Deficiency: Markedly Decreased Reticulocyte PK Activity and Limited Specificity of the PK/HK Ratio.

作者信息

Koleva Larisa, Dolgikh Ivan A, Kryukova Aleksandra V, Prudinnik Dmitry S, Bovt Elizaveta A, Shakhidzhanov Soslan S, Mann Svetlana G, Smetanina Nataliya S, Ataullakhanov Fazoil I, Sinauridze Elena I

机构信息

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samor Mashel Str., 117198 Moscow, Russia.

Center for the Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, 30 Srednyaya Kalitnikovskaya Str., 109029 Moscow, Russia.

出版信息

Int J Mol Sci. 2025 Sep 4;26(17):8606. doi: 10.3390/ijms26178606.

DOI:10.3390/ijms26178606
PMID:40943525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12429783/
Abstract

Diagnosis of pyruvate kinase deficiency (PKD) remains challenging in clinical practice. The pyruvate kinase (PK) to hexokinase (HK) activity ratio (PK/HK) was proposed to reduce the confounding effect of reticulocytosis on PK activity measurement. However, decreased PK activity and PK/HK ratios have also been observed in other anemias, raising doubts about their diagnostic value. We assessed the diagnostic accuracy of PK/HK ratio versus PK activity in differentiating PKD from other hereditary anemias. This study included 41 patients with molecularly confirmed PKD and 62 patients with other anemias. We also evaluated the influence of reticulocytosis and transfusions on erythrocyte PK activity. The PK/HK ratio showed 73% specificity, while PK activity alone achieved 95%. In PKD patients, reticulocytosis did not affect PK activity because reticulocyte PK activity was already markedly reduced (23-fold) compared with controls. In other anemias, decreases in PK activity were present in both reticulocytes and erythrocytes, but to a lesser extent. Transfusions contribute more to the false-normal result of PK activity than reticulocytosis. Measuring reticulocyte-specific PK activity during regular transfusions provided reliable results, as only patient-derived reticulocytes are present in the blood. PK activity demonstrates higher specificity than PK/HK ratio in diagnosing PKD. Reticulocytosis is not a confounder, while transfusions remain the main limitation. Reticulocyte-specific PK activity measurement may improve diagnostic accuracy in transfused patients.

摘要

在临床实践中,丙酮酸激酶缺乏症(PKD)的诊断仍然具有挑战性。有人提出丙酮酸激酶(PK)与己糖激酶(HK)的活性比(PK/HK)可降低网织红细胞增多对PK活性测量的混杂影响。然而,在其他贫血中也观察到PK活性和PK/HK比值降低,这使其诊断价值受到质疑。我们评估了PK/HK比值与PK活性在鉴别PKD和其他遗传性贫血方面的诊断准确性。本研究纳入了41例经分子确诊的PKD患者和62例其他贫血患者。我们还评估了网织红细胞增多和输血对红细胞PK活性的影响。PK/HK比值的特异性为73%,而仅PK活性的特异性达到95%。在PKD患者中,网织红细胞增多不影响PK活性,因为与对照组相比,网织红细胞PK活性已经显著降低(23倍)。在其他贫血中,网织红细胞和红细胞中的PK活性均有下降,但程度较轻。输血比网织红细胞增多对PK活性假正常结果的影响更大。在定期输血期间测量网织红细胞特异性PK活性可提供可靠结果,因为血液中仅存在患者来源的网织红细胞。在诊断PKD时,PK活性比PK/HK比值具有更高的特异性。网织红细胞增多不是混杂因素,而输血仍然是主要限制因素。测量网织红细胞特异性PK活性可能提高输血患者的诊断准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/d978bedf77ce/ijms-26-08606-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/01bfd015776c/ijms-26-08606-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/6888fa759fe6/ijms-26-08606-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/9b3202dea718/ijms-26-08606-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/3499d95ab500/ijms-26-08606-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/a75748841027/ijms-26-08606-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/2da90db4ad10/ijms-26-08606-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/d978bedf77ce/ijms-26-08606-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/01bfd015776c/ijms-26-08606-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/6888fa759fe6/ijms-26-08606-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/9b3202dea718/ijms-26-08606-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/3499d95ab500/ijms-26-08606-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/a75748841027/ijms-26-08606-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/2da90db4ad10/ijms-26-08606-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686b/12429783/d978bedf77ce/ijms-26-08606-g007.jpg

相似文献

1
Pyruvate Kinase Deficiency: Markedly Decreased Reticulocyte PK Activity and Limited Specificity of the PK/HK Ratio.丙酮酸激酶缺乏症:网织红细胞丙酮酸激酶活性显著降低以及丙酮酸激酶/己糖激酶比值的特异性有限。
Int J Mol Sci. 2025 Sep 4;26(17):8606. doi: 10.3390/ijms26178606.
2
The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency.丙酮酸激酶(PK)与己糖激酶酶活性比值和红细胞 PK 蛋白水平在 PK 缺乏症的诊断和表型中的应用。
Br J Haematol. 2021 Mar;192(6):1092-1096. doi: 10.1111/bjh.16724. Epub 2020 May 28.
3
Pyruvate kinase deficiency in children.儿童丙酮酸激酶缺乏症。
Pediatr Blood Cancer. 2021 Sep;68(9):e29148. doi: 10.1002/pbc.29148. Epub 2021 Jun 14.
4
Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane.遗传性球形红细胞增多症与丙酮酸激酶活性降低有关,这是由于红细胞膜的结构完整性受损所致。
Br J Haematol. 2019 Nov;187(3):386-395. doi: 10.1111/bjh.16084. Epub 2019 Jul 5.
5
Pyruvate kinase activators for treatment of pyruvate kinase deficiency.丙酮酸激酶激活剂治疗丙酮酸激酶缺乏症。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):97-106. doi: 10.1182/hematology.2023000466.
6
Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency.解决丙酮酸激酶缺乏症的诊断差距:丙酮酸激酶缺乏症诊断的共识建议。
Am J Hematol. 2019 Jan;94(1):149-161. doi: 10.1002/ajh.25325. Epub 2018 Nov 28.
7
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
8
Screening of hereditary spherocytosis and pyruvate kinase deficiency by automated blood count using erythrocytic and reticulocytic parameters.应用红细胞和网织红细胞参数的自动化血细胞计数筛选遗传性球形红细胞增多症和丙酮酸激酶缺乏症。
Int J Lab Hematol. 2018 Dec;40(6):697-703. doi: 10.1111/ijlh.12906. Epub 2018 Sep 5.
9
Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models - Of mice and men.汤姆斯和伯克利镰状细胞病小鼠模型中的红细胞丙酮酸激酶特性——从鼠到人的研究
Blood Cells Mol Dis. 2025 Mar;111:102909. doi: 10.1016/j.bcmd.2025.102909. Epub 2025 Jan 16.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

本文引用的文献

1
Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease.丙酮酸激酶功能与镰状细胞病中的红细胞特性及临床表现相关。
Am J Hematol. 2025 May;100(5):785-796. doi: 10.1002/ajh.27644. Epub 2025 Feb 21.
2
Pyruvate kinase deficiency in 29 Turkish patients with two novel intronic variants.29 例土耳其丙酮酸激酶缺乏症患者的 2 种新型内含子变异。
Br J Haematol. 2024 Jul;205(1):236-242. doi: 10.1111/bjh.19575. Epub 2024 May 29.
3
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study.
低危骨髓增生异常综合征患者红细胞糖酵解活性及丙酮酸激酶激活剂 AG-946 的体外作用:一项概念验证研究。
Am J Hematol. 2024 Jun;99(6):1201-1204. doi: 10.1002/ajh.27300. Epub 2024 Apr 2.
4
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines.丙酮酸激酶缺乏症的诊断与管理:国际专家指南。
Lancet Haematol. 2024 Mar;11(3):e228-e239. doi: 10.1016/S2352-3026(23)00377-0. Epub 2024 Feb 5.
5
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme.激活丙酮酸激酶作为罕见溶血性贫血的治疗选择:为一种古老的酶带来新的曙光。
Blood Rev. 2023 Sep;61:101103. doi: 10.1016/j.blre.2023.101103. Epub 2023 Jun 12.
6
Pyruvate kinase deficiency mimicking congenital dyserythropoietic anemia type I.丙酮酸激酶缺乏症模拟先天性红细胞生成不良性贫血Ⅰ型。
Turk J Pediatr. 2022;64(5):951-955. doi: 10.24953/turkjped.2021.4704.
7
Pyruvate Kinase Deficiency: Current Challenges and Future Prospects.丙酮酸激酶缺乏症:当前挑战与未来前景
J Blood Med. 2022 Sep 1;13:461-471. doi: 10.2147/JBM.S353907. eCollection 2022.
8
Enzymatic Changes in Red Blood Cells of Diamond-Blackfan Anemia. Diamond-Blackfan 贫血症患者红细胞中的酶变化。
Tohoku J Exp Med. 2021 Sep;255(1):49-55. doi: 10.1620/tjem.255.49.
9
Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy.镰状细胞病中丙酮酸激酶活性和稳定性降低:mitapivat治疗的新靶点。
Blood. 2021 May 27;137(21):2997-3001. doi: 10.1182/blood.2020008635.
10
Management of pyruvate kinase deficiency in children and adults.儿童和成人丙酮酸激酶缺乏症的管理。
Blood. 2020 Sep 10;136(11):1241-1249. doi: 10.1182/blood.2019000945.